drugset / Trial / NCT00475020
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if using a combination of fludarabine, busulfan, and antithymocyte globulin (ATG) can help to control myelofibrosis or myelodysplastic syndrome in patients receiving a bone marrow or blood stem cell transplant. The safety of these drugs will also be studied.
Timeline
- Start
- 2006-01-04
- Primary completion
- 2017-10-04
- Completion
- 2017-10-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Fludarabine | Small molecule | 40 mg/m2 | Intravenous |
| Subject | Thymoglobulin | Protein / enzyme biologic | 2.5 mg/kg | Intravenous |